Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...